Evidence map›Paper›PMID 30027272›Full record

ArticleJAMA ophthalmology2018

Potential Diagnosis of Vitreoretinal Lymphoma by Detection of MYD88 Mutation in Aqueous Humor With Ultrasensitive Droplet Digital Polymerase Chain Reaction.

Laura S Hiemcke-Jiwa, Ninette H Ten Dam-van Loon, Roos J Leguit, Stefan Nierkens, Jeannette Ossewaarde-van Norel, Joke H de Boer, Floor F Roholl, Roel A de Weger, Manon M H Huibers, Jolanda D F de Groot-Mijnes and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in JAMA ophthalmology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed
6.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 83 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Intraocular Lymphoma: A Review.Journal of ophthalmic & vision research · 2025
    Review
  13. Article
  14. Article
  15. Article
  16. [Molecular diagnostics for vitreoretinal lymphoma].Pathologie (Heidelberg, Germany) · 2023
    Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Laura S Hiemcke-JiwaDepartment of Pathology, University Medical Center Utrecht, Utrecht, the Netherlands.
Ninette H Ten Dam-van LoonDeparment of Ophthalmology, University Medical Center Utrecht, Utrecht, the Netherlands.
Roos J LeguitDepartment of Pathology, University Medical Center Utrecht, Utrecht, the Netherlands.
Stefan NierkensLaboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, the Netherlands.
Jeannette Ossewaarde-van NorelDeparment of Ophthalmology, University Medical Center Utrecht, Utrecht, the Netherlands.
Joke H de BoerDeparment of Ophthalmology, University Medical Center Utrecht, Utrecht, the Netherlands.
Floor F RohollDepartment of Pathology, University Medical Center Utrecht, Utrecht, the Netherlands.
Roel A de WegerDepartment of Pathology, University Medical Center Utrecht, Utrecht, the Netherlands.
Manon M H HuibersDepartment of Pathology, University Medical Center Utrecht, Utrecht, the Netherlands.
Jolanda D F de Groot-MijnesDepartment of Medical Microbiology, University Medical Center Utrecht, Utrecht, the Netherlands.
Jonas J W KuiperDeparment of Ophthalmology, University Medical Center Utrecht, Utrecht, the Netherlands.
University Medical Center Utrecht · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Importance: The diagnostic workup of patients suspected of having vitreoretinal lymphoma (VRL) is primarily based on vitreous fluid analysis, including the recently emerging myeloid differentiation primary response gene 88 (MYD88) mutation analysis. Aqueous humor paracentesis is a relatively less invasive and safer procedure than taking vitreous fluid specimens, and aqueous humor-based MYD88 mutation analysis would provide an additional liquid biopsy tool to diagnose and monitor patients with VRL. Objective: To investigate whether the detection of MYD88 L265P by highly sensitive droplet digital polymerase chain reaction (ddPCR) is feasible in the vitreous fluid and aqueous humor of patients with VRL. Design, Setting, and Participants: This cohort study includes aqueous humor and vitreous fluid samples from patients with VRL who were treated at the University Medical Center Utrecht, in Utrecht, the Netherlands, from August 2005 to August 2017. Ocular fluids were randomized and masked before MYD88 L265P analysis, which was performed using an in-house validated ddPCR platform. Patients with uveitis were included as a comparison group. Main Outcomes and Measures: The presence of MYD88 L265P mutation detected by ddPCR in AH and VF. Results: The study included 96 samples from 63 individuals, including 23 patients with VRL (of whom 10 were female and 13 male, with a mean [SD] age of 72 [7.3] years) and 40 individuals with uveitis (of whom 23 were female and 17 male, with a mean [SD] age of 58 [20.9] years). In 17 of 23 patients with VRL (74%), MYD88 L265P was detected; it was not detected in any of the patients with uveitis. It was detectable in both vitreous fluid and aqueous humor samples. In the paired samples, the mutation was detected in 8 of 9 aqueous humor samples (89%) of the MYD88 L265P-positive vitreous fluid samples. In vitreous fluid, the MYD88 ddPCR test showed a sensitivity of 75% (95% CI, 50%-92%) and a positive predictive value of 100%; in aqueous humor, sensitivity was 67% (95% CI, 42%-92%), and positive predictive value was 100%. Specificity was 100% in both fluids. After treatment, the mutation was no longer detectable in any ocular fluids. Conclusions and Relevance: The high concordance between aqueous humor and vitreous fluid samples suggests that use of the easily accessible aqueous humor is nearly as informative as vitreous fluid in the identification of key somatic mutations in patients with VRL. This approach may provide an additional minimally invasive tool for accurate diagnosis, detection of recurrence, and monitoring of treatment.

Indexed as

MutationAgedAged, 80 and overAqueous HumorBiomarkers, TumorCohort StudiesDNA Mutational AnalysisEye NeoplasmsFeasibility StudiesFemaleFlow CytometryHumansIntraocular LymphomaMaleMiddle AgedMyeloid Differentiation Factor 88Biomarkers, TumorMYD88 protein, humanMyeloid Differentiation Factor 88

Identifiers

PMID30027272
PMCPMC6233833
OpenAlexW2884747481

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.